Ronald Knickerbocker
Corporate Officer/Principal chez THESEUS PHARMACEUTICALS, INC.
Profil
Ronald Knickerbocker is currently employed as SVP-Biometrics & Clinical Development Strategy at Theseus Pharmaceuticals, Inc. He previously worked as Head-Statistical Site at Pfizer Inc. from 1999 to 2004, and as Vice President at Genzyme Corp.
from 2004 to 2012.
He also held the position of Vice President-Clinical Development at Anchiano Therapeutics Ltd.
Dr. Knickerbocker received his undergraduate, graduate, and doctorate degrees from Texas A&M University.
Postes actifs de Ronald Knickerbocker
Sociétés | Poste | Début |
---|---|---|
THESEUS PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Anciens postes connus de Ronald Knickerbocker
Sociétés | Poste | Fin |
---|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/01/2012 |
PFIZER, INC. | Corporate Officer/Principal | 01/01/2004 |
ANCHIANO THERAPEUTICS LTD. | Corporate Officer/Principal | - |
Formation de Ronald Knickerbocker
Texas A&M University | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
PFIZER, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
Anchiano Therapeutics Ltd.
Anchiano Therapeutics Ltd. BiotechnologyHealth Technology Anchiano Therapeutics Ltd. is a clinical-stage biopharmaceutical company, which engages in tin the discovery, development and commercialization of drugs for cancer-related diseases. Its products include two drugs for cancer BC-819 and BC-821. The company was founded by Avraham Hochberg in 2004 and is headquartered in Jerusalem, Israel. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Theseus Pharmaceuticals, Inc.
Theseus Pharmaceuticals, Inc. BiotechnologyHealth Technology Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. It focuses on the discovery, development and commercialization of transformative targeted therapies. The company was founded by William C. Shakespeare, David C. Dalgarno, Iain D. Dukes, Wei Sheng Huang and Victor M. Rivera on December 29, 2017 and is headquartered in Cambridge, MA. | Health Technology |